Therapeutic Breakthroughs in Multiple Sclerosis

USD 750

* Required Fields

USD 750

PAY BY INVOICE

Be the first to review this product

This edition of the Future Tech TOE primarily encompasses comprehensive analyses of key emerging therapies across multiple sclerosis (MS). The service also includes treatment overviews, clinical pipeline analysis, IP and funding analysis, and emerging innovations across MS therapies. Furthermore, the research features the impact of key technology drivers and restraints for the global MS therapeutic industry, while providing an overview of the emerging technological landscape for MS treatments.

The Future Tech TechVision Opportunity Engine (TOE) captures emerging innovations in research and development, or profile existing technologies which have seen a resurgence in terms of new markets and applications. It usually provides a technology overview, drivers, challenges, research and development, analyst insights and key patent information. In some cases, technology convergence scenarios and future growth opportunities are outlined. It covers innovations and technologies in a variety of industry spaces including manufacturing, sensors, electronics, information and communications technologies, networks, lighting technologies, healthcare, medical devices, materials and coatings, and developments in the energy sector that contribute toward a sustainable and greener world.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Multiple sclerosis, stem cell therapy, Ocrevus, Ocrelizumab, neurodegenerative disease, Natalizumab, Alemtuzumab, Fingolimod, Teriflunomide, autologous hematopoietic stem cell transplantation (AHSCT), monoclonal antibody treatment

Table of Contents

Therapeutic Breakthroughs in Multiple Sclerosis1.0 Overview of Multiple Sclerosis Treatments1.1 New Therapies on the Horizon for Multiple Sclerosis1.2 Summary of Existing Disease Modifying MS Therapies1.3 Overview of Emerging MS Therapies1.4 Role of Stem Cell Therapy in MS Management1.5 Clinical Pipeline Overview for Late Phase MS Therapies1.6 Clinical Pipeline Overview for Early Phase MS Therapies2.0 Innovation Tracker2.1 Breakthrough Approval for Roche’s Ocrelizumab 2.2 Novartis’s MS Portfolio Expands with Ofatumumab Acquisition2.3 Evaluating Oral Biotin Formulation for Progressive MS2.4 Role of Tyrosine Kinase Inhibitor in Progressive MS2.5 Hematopoietic Stem Cell Therapy for MS Management2.6 Antibody Therapy for Myelin Repair3.0 Impact Analysis and Assessment3.1 Summary of Key Technology Drivers and Restraints3.2 Growing Demand for Targeted Therapies Likely to Fuel New Discoveries across MS Management3.3 High Risk of Treatment Toxicity Still a Major Concern across MS Management4.0 Strategic Insights and Future Perspectives4.1 US Leads the Global IP Landscape for MS Treatments4.2 Analysis of Research Funding for MS Treatments in the US4.3 DMTs Likely to Enhance the Future of MS Management 5.0 Appendix5.1 Key Contacts5.1 Key Contacts (continued)




Related Research

Release Date : 19-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Release Date : 05-May-17

Region : Global

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.